A major bank has approved the Bitwise Solana Staking ETF (BSOL) as collateral for loans, allowing customers to borrow up to 25% of their shares' value. This lending feature lets investors access cash without selling their BSOL shares, which represent staked Solana tokens earning rewards. The approval marks a step toward integrating crypto assets with traditional financial services, although details like interest rates and borrower eligibility remain undisclosed. BSOL holds over 8 million SOL tokens, with a net staking reward rate of 5.84%, offering investors exposure to Solana's growth and staking benefits through a regulated exchange-traded product.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
